Biotech Values

[investorgold2002]

sodrock, u need a coffee break

with all due respect, please take a breather. I just think you guys are READING WAY TOO MUCH of what is essentially an inconsequential news.

keep in mind, TEVA is a bellwether in generic industry and followed by wallstreet analysts and institutional investors closely. they probably have the need for spinning news, maybe for that reason or it could even be innocent mistake by some third party journalist. copaxone indeed is 25-30% of their margin(so big).
that september date doesnt make sense. they had to respond by 180 day deadline.
But the bottomline is for MNTA investor this PR is inconsequential..even if share price goes to $15...It doesn't affect the way FDA would make the decision on ANDA. Of more importance on this issue would be the fact that, FDA took 7 months to review ANDA before acceptance, MNTA states that they continue to have positive discussions although at very slow pace, MNTA's Copaxone assay patent that is out there which along with characterization patent would technically satisfy the sameness criteria(as detailed Lovenox CP response), etc